1. Home
  2. ACB vs CRBU Comparison

ACB vs CRBU Comparison

Compare ACB & CRBU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Aurora Cannabis Inc.

ACB

Aurora Cannabis Inc.

HOLD

Current Price

$3.68

Market Cap

188.3M

Sector

Health Care

ML Signal

HOLD

Logo Caribou Biosciences Inc.

CRBU

Caribou Biosciences Inc.

HOLD

Current Price

$2.20

Market Cap

179.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ACB
CRBU
Founded
2013
2011
Country
Canada
United States
Employees
N/A
N/A
Industry
Pharmaceuticals and Biotechnology
Medicinal Chemicals and Botanical Products
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
188.3M
179.7M
IPO Year
2016
2021

Fundamental Metrics

Financial Performance
Metric
ACB
CRBU
Price
$3.68
$2.20
Analyst Decision
Strong Buy
Analyst Count
0
4
Target Price
N/A
$10.75
AVG Volume (30 Days)
587.5K
1.0M
Earning Date
02-04-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
3.64
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$6.31
$1.63
Revenue Next Year
N/A
$10.93
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$3.07
$0.72
52 Week High
$6.67
$3.53

Technical Indicators

Market Signals
Indicator
ACB
CRBU
Relative Strength Index (RSI) 61.00 64.47
Support Level $3.28 $1.70
Resistance Level $3.91 $2.26
Average True Range (ATR) 0.14 0.12
MACD 0.05 0.02
Stochastic Oscillator 97.71 97.09

Price Performance

Historical Comparison
ACB
CRBU

About ACB Aurora Cannabis Inc.

Aurora Cannabis Inc headquartered in Edmonton, Canada, cultivates and sells medicinal and recreational cannabis through a portfolio of brands that includes Drift, San Rafael '71, Daily Special, Whistler, Being, and Greybeard. Although the company operates in Canada, it has expanded internationally through medical cannabis exporting agreements. The company opertes in Canada, Europe, Australia, and Others, with majority revenue from Canada.

About CRBU Caribou Biosciences Inc.

Caribou Biosciences Inc is a clinical-stage Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) genome-editing biopharmaceutical company dedicated to developing transformative therapies for patients with devastating diseases. The company is focused on advancing two clinical-stage allogeneic CAR-T cell therapy product candidates for the treatment of patients with hematologic malignancies: Vispacabtagene regedleucel and CB-011. It operates in one reportable segment, which is the business of developing allogeneic CAR-T cell therapies. Geographically, it operates in the United States and the rest of the World, of which the United States derives the maximum revenue.

Share on Social Networks: